908 Devices (MASS) Cash from Financing Activities (2020 - 2026)
908 Devices (MASS) posted quarterly Cash from Financing Activities of -$2.2 million for Q1 2026, down 1047.09% year-over-year from $228911.7 in Q1 2025, and down 423.67% quarter-over-quarter from -$414000.0 in Q4 2025.
908 Devices (MASS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
908 Devices (MASS) has reported Cash from Financing Activities for 7 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 1047.09% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$2.7 million (down 466.58% YoY), while the FY2025 annual figure was -$697000.0, down 85.37% from the prior year.
- Cash from Financing Activities fell to -$2.2 million in Q1 2026 per MASS's latest filing, from -$414000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $529000.0 in Q4 2024 and bottomed at -$15.4 million in Q1 2023.
- Historically, Cash from Financing Activities has averaged -$1.1 million across 5 years, with a median of -$16000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 11931.54% — and 2024, when it soared 456.84%.
- 908 Devices' Cash from Financing Activities stood at $411000.0 in 2022, then tumbled by 76.89% to $95000.0 in 2023, then jumped by 456.84% to $529000.0 in 2024, then tumbled by 178.26% to -$414000.0 in 2025, then tumbled by 423.67% to -$2.2 million in 2026.
- Business Quant data shows MASS's Cash from Financing Activities at -$2.2 million in Q1 2026, -$414000.0 in Q4 2025, and -$16000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | 908 Devices | 398.03 Mn | 296.50 Mn | 8.34 Mn | 965,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 965,000.00 |
| Jun 30, 2026 | 965,000.00 |
| Mar 31, 2026 | -2.17 Mn |
| Mar 31, 2026 | -2.17 Mn |
| Dec 31, 2025 | -414,000.00 |
| Dec 31, 2025 | -414,000.00 |
| Sep 30, 2025 | -16,000.00 |
| Sep 30, 2025 | -16,000.00 |
| Jun 30, 2025 | -78,000.00 |
| Jun 30, 2025 | -78,000.00 |
| Mar 31, 2025 | -189,000.00 |
| Mar 31, 2025 | -189,000.00 |
| Dec 31, 2024 | 529,000.00 |
| Dec 31, 2024 | 529,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Mar 31, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.30 Mn |